Akut Pulmoner Emboli'de Galectin-3

- , 01.03.2020

Mustafa Çelik , Ahmet Avcı Recep Karataş Ahmet Erseçgin Fikret Keleş Ahmet Yılmaz , Fatmagül Can Erdoğan Sökmen , Murat Erer

https://doi.org/10.16919/bozoktip.526355

Cited By: 1

Öz

Amaç: Pulmoner
emboli (PE) göreceli olarak yaygın bir kardiyovasküler acil durumdur ve
spesifik olmayan klinik tablo nedeniyle gözden kaçırılabilecek zor bir tanıdır.
PE' nin patogenezi iyi tanımlanmış olmasına rağmen, PE' nin teşhisine yardımcı
olabilecek klinik bir biyobelirteçlere ihtiyaç vardır. Teorik olarak,
Galectin-3'ün (Gal-3) prokoagülan etkisinden dolayı,  PE'nin patogenezindeki  rol alabileceği düşünülebilir. Bu çalışmanın
amacı, akut PE'li hastalarda Gal-3 düzeyinin önemini göstermek ve PE'nin
ekokardiyografik özellikleri ile ilişkiyi tanımlamaktır.

 Yöntem:  2013 - 2014 tarihleri ​​arasında art arda 40
PE hastası (26 kadın, ort. Yaş 60.93 ± 14.28 yıl) ve 40 yaş uyumlu sağlıklı
kontrol çalışmaya dahil edildi. Gal-3, D-dimer ve Troponin I ölçüldü. PE ve
kontrol grubundaki tüm hastalara transtorasik ekokardiyografik inceleme
yapıldı.

 Bulgular:
Gal-3 ve D-dimer düzeyleri PE' li hastalarda kontrollere göre anlamlı derecede
yüksek bulundu (17.04 ± 6.6 ve 8.22 ± 4.9, p <0.001). Gal-3 seviyeleri, D- dimer
 (r = 0.595, p <0.001) ve Troponin I
değerleri (r = 0.452, p <0.001) ile anlamlı bir korelasyon gösterdi. Gal-3
seviyeleri ekokardiyografik parametrelerle anlamlı korelasyon gösterdi. ROC eğrisi
analizinde,% 82.5 duyarlılık ve% 82.7 özgüllük ile akut PE tanısı için gereken
seviye 11.43 ng / ml idi. Eğri altındaki alan% 95 CI 0.79-0.96 (p <0.001)
ile 0.88 idi.

Sonuç: Bu
çalışmada akut PE'li hastalarda Gal-3'ün rolü gösterilmiştir. Gal-3, akut PE' yi
teşhis etmek için kullanılabilecek biyobelirteçler arasında yer alabilir.ancak
daha kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Galectin-3, D-dimer, Akut pulmoner emboli, Biyobelirteç, Ekokardiyografi

Kaynakça

• Referans1- Wood KE. Major pulmonary embolism: review of a pathophysiologicapproach to the golden hour of hemodynamically significant pulmonary embolism.Chest 2002;121:877–905.
• Referans2- Konstantinides S. Pulmonary embolism: impact of right ventriculardysfunction. Curr Opin Cardiol 2005;20: 496–501.
• Referans3- Alikhan R, Peters F, Wilmott R, and Cohen AT. Fatal pulmonary embolismin hospitalised patients: a necropsy review. J Clin Pathol 2004;57: 1254–57.
• Referans4- Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245–48.
• Referans5- de Boer RA, Yu L, and van Veldhuisen DJ. Galactin-3 in cardiac remodelingand heart failure. Curr Heart Fail Rep 2010;7: 1-8.
• Referans6- Kimura Y, Izumiya Y, Hanatani S, Yamamoto E, Kusaka H, Tokitsu T, et al.High serum levels of thrombospondin-2 correlate with poor prognosis of patients withheart failure with preserved ejection fraction. Heart Vessels 2014; DOI:10.1007/s00380-014-0571-y.
• Referans7- Pacienza N, Pozner RG, Bianco GA, D'Atri LP, Croci DO, Negrotto S, et al.The immunoregulatory glycan-binding protein galectin-1 triggers human plateletactivation.FASEB J 2008;22:1113-23.
• Referans8- Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S,et al. Galectin-3 plasma levels and coronary artery disease: a new possiblebiomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905
• Referans9- Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E,et al. Galectin-3 and the Development of Heart Failure after Acute CoronarySyndrome: Pilot Experience from PROVE IT-TIMI 22. Clin Chem 2012;58: 267-73.
• Referans10- Ramacciotti E, Hawley AE, Wrobleski SK, Myers DD Jr, StrahlerJR, Andrews PC, et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res 2010;125:269-74.
• Referans11- Samuel Z Goldhaber, and Henri Bounameaux. Pulmonary embolism anddeep vein thrombosis. Lancet 2012; 379:1835–46.
• Referans12- Diaz JA, Ramacciotti E, and Wakefield TW. Do galectins play a role invenous thrombosis? a review. Thrombosis Research 2010;125:373–6.
• Referans13- Schattner M, and Rabinovich GA. Galectins: new agonists of plateletactivation. Biol. Chem 2013;394: 857–63.
• Referans14- Kamal FA, Watanabe K, Ma M, Abe Y, Elbarbary R, Kodama M, et al. Anovel phenylpyridazinone, T-3999, reduces the progression of autoimmunemyocarditis to dilated cardiomyopathy. Heart Vessels 2011;26: 81-90.
• Referans15- Gao P, Simpson JL, Zhang J, and Gibson PG. Galectin-3: its role inasthma and potential as an anti-inflammatory target. Respir Res 2013;14: 136.
• Referans16- Saint-Lu N, Oortwijn BD, Pegon JN, Odouard S, Christophe OD, de GrootPG, et al. Identification of Galectin-1 and Galectin-3 as Novel Partners for VonWillebrand Factor. Arterioscler Thromb Vasc Biol 2012;32: 894-901.
• Referans17- Roda O, Ortiz-Zapater E, Martinez-Bosch N, Gutierrez-Gallego R, Vila-Perello M, Ampurdanes C, et al. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 2009;136:1379-90.
• Referans18- Nagaoka MR, Strital E, Kouyoumdjian M, and Borges DR. Participation ofa galectin-dependent mechanism in the hepatic clearance of tissue-type plasminogenactivator and plasma kallikrein. Thromb Res 2002;108:257–62.
• Referans19- Righini M, Perrier A, De Moerloose P, and Bounameaux H. D-Dimer forvenous thromboembolism diagnosis: 20 years later. J Thromb Haemost2008;6: 1059–71.
• Referans20- Righini M, Le Gal G, Perrier A, and Bounameaux H. The challenge ofdiagnosing pulmonary embolism in elderly patients: infl uence of age on commonlyused diagnostic tests and strategies. J Am Geriatr Soc 2005;53: 1039–45.
• Referans21- Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, etal. Guidelines on the diagnosis and management of acute pulmonary embolism.European Heart Journal 2008;29: 2276–315.
• Referans22- Aaron B. Holley, Cheatham JG, Jackson JL, Moores LK, and Villines TC.Novel quantitative echocardiographic parameters in acute PE. J ThrombThrombolysis 2009;28: 506–12.
• Referans23- Cooper JW, Nanda NC, Philpot EF, and Fan P. Evaluation of valvularregurgitation by color Doppler. J Am Soc Echocardiography 1989;2: 56–66.
• Referans24- Di Salvo TG, Mathier M, Semigran MJ, and Dec GW. Preserved rightventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995;25: 1143-53.
• Referans25- Nass N, McConnell MV, Goldhaber SZ, Chyu S, and Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonaryembolism. Am J Cardiol 1999;83: 804-6.
• Referans26- Jaff MR, Mc Murtry MS, Archer SL, Jaff MRCushman M, GoldenbergN, Goldhaber SZ, Jenkins JS, et al. Management of massive and submassivepulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolicpulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:1788-1830.
• Referans27- Torbicki A, Pruszczyk P, and Kurzyna M. Pulmonary embolism: role ofechocardiography and of biological markers. Ital Heart J 2005;6: 805–10.Referans28- Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in thecommunity. J Am Coll Cardiol 2012;60: 1249-56.
• Referans29- Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, andJanuzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12: 826
• Referans30- Peacock WF, and DiSomma S. Emergency department use of galectin-3.Crit Pathw Cardiol 2014;13: 73-7.